Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Solid Tumors 2Thrombocythemia, Essential 1Polycythemia Vera 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Glioblastoma 1Chromosome 17 deletion 1

Interventions

Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 17Cyclophosphamide 17Busulfan 12Tacrolimus 11Methotrexate 8Cyclosporine 8Antilymphocyte Serum 8Whole-Body Irradiation 7Mycophenolic Acid 7Filgrastim 6peginterferon alfa-2a 5Etoposide 5Prednisone 4Decitabine 4Cytarabine 4ruxolitinib 3fludarabine 3Radiotherapy 3Methylprednisolone 3Carboplatin 3Aspirin 3tipifarnib 2sonidegib 2merphos 2liposomal amphotericin B 2givinostat hydrochloride 2givinostat 2aldesleukin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thrombocythemia, Essential × RG7388 × Clear all
NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡